TPI-1
Based on 20 publication(s) in Google Scholar
TPI-1, also known as Tyrosine Phosphatase Inhibitor 1, is a SHP-1 inhibitor; inhibits recombinant SHP-1 with an IC50 of 40 nM.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 79756-69-7
- Formula: C12H6Cl2O2
- Molecular Weight:253.08
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Phosphatase Inhibitor Library
HY-L081
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) TPI-1
More- Immunity. 2026 Mar 6:S1074-7613(26)00040-3. [Abstract]
- Nat Metab. 2021 Apr;3(4):513-522. [Abstract]
- Cancer Res. 2022 May 16;82(10):1991-2002. [Abstract]
- J Allergy Clin Immunol. 2022 Jan;149(1):223-236.e6. [Abstract]
- J Immunother Cancer. 2025 Apr 17;13(4):e010879. [Abstract]
- Cancer Lett. 2026 Apr 10:643:218288. [Abstract]
- J Neuroinflammation. 2020 Mar 9;17(1):81. [Abstract]
- Phytother Res. 2025 Jul;39(7):3033-3045. [Abstract]
- Front Immunol. 2022 Jun 10:13:865503. [Abstract]
- Front Immunol. 2021 Jan 21:11:610523. [Abstract]
- PLoS Pathog. 2024 Oct 29;20(10):e1012674. [Abstract]
- Int Immunopharmacol. 2022 Sep:110:109063. [Abstract]
- Am J Physiol Cell Physiol. 2022 Aug 1;323(2):C650. [Abstract]
- J Neurochem. 2025 Jan;169(1):e16230. [Abstract]
- Cell Signal. 2026 Feb:138:112204. [Abstract]
- Cell Signal. 2025 Nov:135:112051. [Abstract]
- J Immunol Res. 2020 Jun 19;2020:4598476. [Abstract]
- J Stroke Cerebrovasc Dis. 2022 Aug;31(8):106570. [Abstract]
- Charles University. 2026.
- bioRxiv. 2025 Jul 7:2025.07.04.663030. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
WB
-
ELISA
-
RT-PCR
-
WB
Biological Activity
IC50: 40 nM (recombinant SHP-1)[1]
SHP-1 has been implicated as a potential cancer therapeutic target. TPI-1 is effective starting at 10 ng/mL in increasing SHP-1 phospho-substrates pLck-pY394. TPI-1 selectively increases SHP-1 phospho-substrates (pLck-pY394, pZap70 and pSlp76) in Jurkat T cells but has little effects on pERK1/2 or pLck-pY505. TPI-1 induces mouse splenic-IFNγ+ cells and induces IFNγ+ cells in human peripheral blood[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 79756-69-7
-
Appearance Solid
-
Molecular Weight 253.08
-
Formula C12H6Cl2O2
-
Color White to yellow
-
SMILES
ClC1=CC(C2=CC(C=CC2=O)=O)=C(Cl)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Macrophage metabolic exhaustion and PANoptotic cell death drive chronic tissue inflammation in rheumatoid arthritis. [Abstract]2026 Mar 6:S1074-7613(26)00040-3. PMID: 41794034 -
Nat Metab
Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation. [Abstract]2021 Apr;3(4):513-522. PMID: 33846641 -
Cancer Res
Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis. [Abstract]2022 May 16;82(10):1991-2002. PMID: 35364609 -
J Allergy Clin Immunol
LAIR-1 acts as an immune checkpoint on activated ILC2s and regulates the induction of airway hyperreactivity. [Abstract]2022 Jan;149(1):223-236.e6. PMID: 34144112
TPI-1 purchased from MedChemExpress. Usage Cited in: J Allergy Clin Immunol. 2022 Jan;149(1):223-236.e6. [Abstract]
TPI-1 (15 μM). Representative histograms of SHP-1 expression in WT and LAIR-1 KO ILC2s and their corresponding MFI quantification.
-
J Immunother Cancer
Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition. [Abstract]2025 Apr 17;13(4):e010879. PMID: 40246583
TPI-1 purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2025 Apr 17;13(4):e010879. [Abstract]
Mice bearing YUMM 1.1 tumors were treated intraperitoneally (i.p.) with TPI-1 (3 mg/kg) in combination with ICI (anti-PD-1 and anti-CTLA), or singly with either TPI-1 or ICI, every 3 days beginning at the time of tumor visibility (day 7–10).
-
Cancer Lett
Neutrophil extracellular traps enhance platinum resistance in ovarian cancer via SHP-1 activation. [Abstract]2026 Apr 10:643:218288. PMID: 41620200 -
J Neuroinflammation
2020 Mar 9;17(1):81. PMID: 32151250
TPI-1 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2020 Mar 9;17(1):81. [Abstract]
After overexpressing DJ-1 and inhibiting SHP-1 with virus and TPI-1 (10 ng/ml), respectively, the expression of NLRX1, TRAF6 and SHP-1 in rat brain tissue was detected by Western blotting.
-
Phytother Res
Quercetin Alleviates Chronic Urticaria by Negatively Regulating IgE-Mediated Mast Cell Activation Through CD300f. [Abstract]2025 Jul;39(7):3033-3045. PMID: 40309955 -
Front Immunol
Antibody-Mediated LILRB2-Receptor Antagonism Induces Human Myeloid-Derived Suppressor Cells to Kill Mycobacterium tuberculosis. [Abstract]2022 Jun 10:13:865503. PMID: 35757769
TPI-1 purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jun 10:13:865503. [Abstract]
TPI-1 (1 μg/mL). Supernatant was collected 18 hours post-infection, and cytokines were detected using a sandwich ELISA method.
-
Front Immunol
SIRPα Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients. [Abstract]2021 Jan 21:11:610523. PMID: 33552071 -
PLoS Pathog
The protein segregase VCP/p97 promotes host antifungal defense via regulation of SYK activation. [Abstract]2024 Oct 29;20(10):e1012674. PMID: 39471181
TPI-1 purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2024 Oct 29;20(10):e1012674. [Abstract]
Wild-type and VCP-deficient BMDM cells were pretreated with DMSO or the SHP1 inhibitor TPI-1 (10 μM) for 1 hour, then stimulated with ZymD at specified time points, followed by Western blot analysis.
-
Int Immunopharmacol
Clarithromycin-treated chronic spontaneous urticaria with the negative regulation of FcεRΙ and MRGPRX2 activation via CD300f. [Abstract]2022 Sep:110:109063. PMID: 35853276 -
Am J Physiol Cell Physiol
Retraction for Su et al., SHP-1 aggravates obesity-related glomerulopathy and palmitic acid-induced podocyte injury via regulating the PI3K/Nrf2/SIRT1 axis. [Abstract]2022 Aug 1;323(2):C650. PMID: 35264015 -
J Neurochem
DJ-1 regulates astrocyte activation through miR-155/SHP-1 signaling in cerebral ischemia/reperfusion injury. [Abstract]2025 Jan;169(1):e16230. PMID: 39323054 -
Cell Signal
Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling. [Abstract]2026 Feb:138:112204. PMID: 41177417 -
Cell Signal
Combination of Cbl-b inhibitor NX-1607 and CDK4/6 inhibitor abemaciclib enhances anti-tumor immunity through PLCγ1/ERK-mediated T cell activation. [Abstract]2025 Nov:135:112051. PMID: 40774352 -
J Immunol Res
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways. [Abstract]2020 Jun 19;2020:4598476. PMID: 33123602 -
J Stroke Cerebrovasc Dis
Downregulation of NF-κB by Shp-1 Alleviates Cerebral Venous Sinus Thrombosis-Induced Brain Edema Via Suppression of AQP4. [Abstract]2022 Aug;31(8):106570. PMID: 35636226 -
-
bioRxiv
2025 Jul 7:2025.07.04.663030. PMID: 40672291
Solvent & Solubility
DMSO : 50 mg/mL (197.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Mice: For in vivo induction of pLck-pY394 and IFNγ+ cells in mice, C57BL/6J mice are treated with PBS or TPI-1 (1 or 3 mg/kg, s.c.) for 4 days. Spleens are harvested one hour post-treatment on day 4 and processed into splenocytes, which are used for assessing pLck-pY394 levels by SDS-PAGE/Western blotting and for quantification of IFNγ+ cells by ELISPOT assays. Mice are also treated with TPI-1 (10 mg/kg, daily, s.c.) to evaluate the toxicity of the compounds in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9513 mL | 19.7566 mL | 39.5132 mL | 98.7830 mL |
| 5 mM | 0.7903 mL | 3.9513 mL | 7.9026 mL | 19.7566 mL | |
| 10 mM | 0.3951 mL | 1.9757 mL | 3.9513 mL | 9.8783 mL | |
| 15 mM | 0.2634 mL | 1.3171 mL | 2.6342 mL | 6.5855 mL | |
| 20 mM | 0.1976 mL | 0.9878 mL | 1.9757 mL | 4.9391 mL | |
| 25 mM | 0.1581 mL | 0.7903 mL | 1.5805 mL | 3.9513 mL | |
| 30 mM | 0.1317 mL | 0.6586 mL | 1.3171 mL | 3.2928 mL | |
| 40 mM | 0.0988 mL | 0.4939 mL | 0.9878 mL | 2.4696 mL | |
| 50 mM | 0.0790 mL | 0.3951 mL | 0.7903 mL | 1.9757 mL | |
| 60 mM | 0.0659 mL | 0.3293 mL | 0.6586 mL | 1.6464 mL | |
| 80 mM | 0.0494 mL | 0.2470 mL | 0.4939 mL | 1.2348 mL | |
| 100 mM | 0.0395 mL | 0.1976 mL | 0.3951 mL | 0.9878 mL |
Powered by Bioz